Literature DB >> 18032103

Melatonin receptors: role on sleep and circadian rhythm regulation.

Margarita L Dubocovich1.   

Abstract

The circadian release of the hormone melatonin is regulated by the suprachiasmatic nucleus (SCN), which feeds back into the nucleus to modulate sleep and circadian phase through activation of the MT(1) and/or MT(2) melatonin receptors. Considering the functions of the SCN as a sleep and circadian rhythm regulator, melatonin and melatonin receptor agonists have attracted interest as being possible treatments for sleep and circadian rhythm sleep disorders. Part of this interest has centered on elucidating which melatonin receptors are targets for the regulation of these functions within the SCN. Two G-protein coupled melatonin receptors, the MT(1) and MT(2), inhibit neuronal activity and phase shift circadian firing rhythms in the SCN, respectively. Recent reports have uncovered possible interactions between the two types of receptors in the mammalian SCN, as well as the role of physiological and supraphysiological levels of melatonin on the molecular pharmacology and cellular changes of human and rodent melatonin receptors via desensitization and internalization mechanisms. These data outline the complexity of the interplay between melatonin and its receptors in the SCN and their corresponding roles in sleep and circadian regulation. Although further studies are necessary, a great deal of progress has been made toward understanding how melatonin and its agonists contribute to sleep and circadian phase changes, and how best to develop compounds that can target the functions of the SCN specifically and effectively.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18032103     DOI: 10.1016/j.sleep.2007.10.007

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  85 in total

Review 1.  Does inadequate sleep play a role in vulnerability to obesity?

Authors:  Kristen L Knutson
Journal:  Am J Hum Biol       Date:  2012-01-24       Impact factor: 1.937

2.  Circadian periods of sensitivity for ramelteon on the onset of running-wheel activity and the peak of suprachiasmatic nucleus neuronal firing rhythms in C3H/HeN mice.

Authors:  Oliver Rawashdeh; Randall L Hudson; Iwona Stepien; Margarita L Dubocovich
Journal:  Chronobiol Int       Date:  2011-02       Impact factor: 2.877

3.  How to fix a broken clock.

Authors:  Analyne M Schroeder; Christopher S Colwell
Journal:  Trends Pharmacol Sci       Date:  2013-10-10       Impact factor: 14.819

Review 4.  Illuminating rationale and uses for light therapy.

Authors:  Afshin Shirani; Erik K St Louis
Journal:  J Clin Sleep Med       Date:  2009-04-15       Impact factor: 4.062

5.  The use of melatonin in Swedish children and adolescents--a register-based study according to age, gender, and medication of ADHD.

Authors:  Catrin Furster; Maria Unenge Hallerbäck
Journal:  Eur J Clin Pharmacol       Date:  2015-05-22       Impact factor: 2.953

Review 6.  Bright light therapy in the treatment of childhood and adolescence depression, antepartum depression, and eating disorders.

Authors:  Krzysztof Krysta; Marek Krzystanek; Małgorzata Janas-Kozik; Irena Krupka-Matuszczyk
Journal:  J Neural Transm (Vienna)       Date:  2012-07-19       Impact factor: 3.575

7.  Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia.

Authors:  Geert Mayer; Sherry Wang-Weigand; Barbara Roth-Schechter; Reiner Lehmann; Corinne Staner; Markku Partinen
Journal:  Sleep       Date:  2009-03       Impact factor: 5.849

8.  Use of transdermal melatonin delivery to improve sleep maintenance during daytime.

Authors:  D Aeschbach; B J Lockyer; D-J Dijk; S W Lockley; E S Nuwayser; L D Nichols; C A Czeisler
Journal:  Clin Pharmacol Ther       Date:  2009-07-15       Impact factor: 6.875

9.  MTNR1B rs10830963 is associated with fasting plasma glucose, HbA1C and impaired beta-cell function in Chinese Hans from Shanghai.

Authors:  Chen Liu; Ying Wu; Huaixing Li; Qibin Qi; Claudia Langenberg; Ruth J F Loos; Xu Lin
Journal:  BMC Med Genet       Date:  2010-04-14       Impact factor: 2.103

10.  Sleep-promoting action of IIK7, a selective MT2 melatonin receptor agonist in the rat.

Authors:  Simon P Fisher; David Sugden
Journal:  Neurosci Lett       Date:  2009-04-07       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.